ABSTRACT

Alzheimer’s disease (AD) affects many people around the world, and its incidence is increasing. In addition to the amyloid cascade hypothesis, different mechanisms are discussed for AD, which has no definitive treatment. Studies have shown that the levels of metal cations such as iron, copper, zinc, and magnesium vary and their metabolism are impaired in patients with AD. Metal cation dyshomeostasis is believed to be one of the mechanisms that contribute to the development of AD. In this review, we aimed to evaluate various metal cations in terms of AD.

Keywords:

Alzheimer’s disease, dyshomeostasis, iron, copper, zinc, magnesium

INTRODUCTION

Dementia is a neuropsychiatric medical condition that causes deterioration in people’s cognitive abilities compared to a few months or a few years ago and is characterized by deterioration in activities of daily living (1). The incidence of dementia increases with the prolongation of the human lifespan. Alzheimer’s disease (AD) is the most common cause of dementia and affects many people worldwide. Although AD is a disease that usually occurs in advanced age, it cannot be considered as a part of normal aging (2). While AD causes behavioral and speech changes by disrupting the cognitive activities of patients, it also negatively affects the quality of life of patients’ relatives (1,2).

In addition to the large number of people affected, there is still no curative treatment for AD (3). Acetylcholine esterase inhibitors such as donepezil, rivastigmine, galantamine, and the N-methyl D-aspartate (NMDA) receptor antagonist memantine are used in this treatment. These treatments are only aimed at slowing the disease progression. They are insufficient to treat the disease, and there is a problem of tolerance to these drugs (3,4). The effectiveness of the monoclonal antibody aducanumab, which was approved by the US Food and Drug Administration (FDA) in 2021, for treating the disease is controversial (4). Lecanemab, another anti-Aβ monoclonal antibody, was approved by the FDA in 2023. It is emphasized that lecanemab, which targets the soluble and insoluble forms of the Aβ peptide accumulated in AD, can reduce Aβ aggregates in the brain. It has been stated that lecanemab can be effective, especially in the early stages of AD, and results are needed to demonstrate its clinical benefit (5,6). There is currently no curative treatment for AD.

In addition to the lack of an effective treatment for AD, no biomarker can make a definitive diagnosis alone. Although various biomarkers have been tried for the diagnosis of AD, these options do not provide high specificity and sensitivity criteria and remain far from making a definitive diagnosis (7). The fact that the biomarker considered for AD is blood-based and minimally invasive will provide a great advantage in terms of ease of application (8). Therefore, various plasma parameters have been evaluated for their potential as biomarkers for AD.

Metal cations such as iron, copper, and zinc are currently being investigated because of their association with AD (9,10). In addition, in recent years, it has been emphasized that various forms of magnesium are important for AD. With its anti-inflammatory properties, magnesium is believed to be beneficial in AD, as in many other neurological diseases (11).

Changes in plasma and urinary metal cation levels in patients with Alzheimer’s have led scientists to work on this issue. For example, in various studies, plasma copper levels in patients with Alzheimer’s were found to be significantly higher than in controls. It has been reported that urinary copper excretion is also high in patients with AD. These findings indicate the presence of metal cation dyshomeostasis in patients with AD (12).

This review aims to evaluate various metal cations (iron, copper, zinc and magnesium) in terms of AD. The specified metal cations are the most important for AD, and their dyshomeostasis further influences disease development. This study aimed to review the literature by examining the metals that may be related to AD, which does not have a definitive diagnosis and curative treatment yet. Explaining the mechanism could lead to the development of future AD treatments targeting metal cations.

Alzheimer’s Disease and Metal Cations

AD is the most common form of dementia and affects many people around the world. Pathological accumulations are observed during the development of AD. These are intracellular neurofibrillary tangles and extracellular amyloid plaques. The accumulation of amyloid plaque and the accumulation of hyperphosphorylated tau protein act as triggers for each other. In the continuation of the process, clinical signs of AD are observed due to neuronal loss and deterioration of synaptic transmission (13).

Although age is the most prominent factor in the development of AD, life expectancy is increasing in many countries. In addition, AD cannot be considered as a result of normal aging (2). Therefore, studies should be conducted for AD, which has not a curative treatment and a biomarker that will provide a definitive diagnosis. However, it will be beneficial to elucidate the unknown parts of the development mechanisms of the disease.

In recent years, mechanisms other than the amyloid cascade hypothesis have been investigated for the development of AD. This is caused by the ineffectiveness of treatments targeting amyloid deposition and the fact that AD is a multifactorial disease (14).

Balance of metal cations in the central nervous system is necessary for healthy brain function. For this reason, metal cation homeostasis was investigated for AD using different mechanisms (Figure 1) (14). Metals cross the blood-brain barrier endothelium via active or receptor-mediated transporters to serve essential roles as secondary messengers, enzyme activators, and gene expression regulators in the brain. Therefore, the delicate brain balance of metal concentrations must be maintained (15).

In this review, the possible relationships between some metal cations and AD were investigated.

Iron in Alzheimer’s Disease

Iron, the most abundant transition metal in the brain, is essential for healthy living and proper functioning of the brain. Iron is a cofactor in many processes, including gene expression, neuronal development, enzymatic reactionshome protein formation, and electron transport (16). However, iron dyshomeostasis is closely related to oxidative stress. When the amount of iron exceeds the detoxification capacity of the cell, increased iron levels cause the amplification of oxidative stress by the Fenton reaction and the Haber-Weiss cycle. Therefore, oxidative stress due to iron accumulation in the brain causes neuronal damage (17).

Iron levels vary in Alzheimer’s patients Iron binds directly to Aβ and tau, causing biochemical modifications that generate oxygen radicals that amplify cell-wide oxidative stress (14). Alternative treatments are sought because amyloid-targeted therapies cannot show the desired efficacy in AD. Homeostatic regulation of iron is a viable avenue for therapeutic targeting and has been observed to be impaired in many neurodegenerative disorders in addition to AD (18).

Amyloid precursor protein (APP) and tau proteins, which play a role in AD development, are associated with iron metabolism (19). In neurons, the concentration of iron ions is effective in APP gene expression. APP mRNA has a segment of 11 bases in the 5’ region called the iron regulatory element (IRE). Iron regulatory proteins (IRPs) associate with IRE to regulate APP synthesis (20). Iron regulatory proteins associate with IREs in the untranslated region of mRNA transcripts of iron metabolism-related genes, thereby regulating iron concentration in cells. High iron concentrations increase APP expression by causing conformational changes in the IRE region of APP mRNA. In addition, high concentrations of iron in the neurons cause APP to be proteolyse to form amyloid deposits (21).

The iron regulatory proteins IRP1 and IRP2 are intracellular iron sensors. The regulation of brain iron homeostasis at the cellular level includes IRPs that regulate the expression of related proteins. A decrease in IRP2 expression levels leads to an imbalance in brain iron. In addition, oxidative stress caused by iron accumulation in the brain increases IRP1 activity, causing a further increase in intracellular free iron (22,23). This increase in iron can lead to the development of neurodegenerative diseases such as AD (24).

Iron accumulates in the brain with age, and several neurodegenerative conditions are associated with increased iron levels in affected areas of the brain. Iron accumulation is observed in the parietal cortex, motor cortex, and hippocampus, which are brain regions of primary importance in AD (25,26). Age-related iron deposition in brain regions associated with AD has made iron dyshomeostasis a therapeutic target for AD (18).

In addition, iron-dependent programed cell death, called ferroptosis, causes many diseases, particularly neurodegenerative diseases. Iron dyshomeostasis and lipid peroxidation, which are hallmarks of ferroptosis, play an important role in the development of AD, a neurodegenerative disease (27,28).

Copper in Alzheimer’s Disease

Aβ senile amyloid plaques in Alzheimer’s patients contain high levels of metal cations. These metal cations are especially iron, copper, and zinc. Metal accumulation in amyloid plaques demonstrates the effect of metal cation dyshomeostasis on AD development (12,29). Senile amyloid plaques contain high concentrations of iron, copper, and zinc, and these ions can trigger Aβ accumulation (30).

In a study conducted with 336 healthy controls, 385 Alzheimer’s patients, and 9 Wilson’s patients, plasma copper levels were found to be higher in Alzheimer’s patients, similar to Wilson’s patients. These findings have been interpreted as an indicator of deterioration in copper homeostasis in AD. In the same study, urinary copper excretion was high in Alzheimer’s patients compared with healthy controls in 24-h urine measurements (12).

In another study conducted with 50 patients with AD and 50 healthy controls, plasma iron, copper, and zinc levels were found to be significantly lower in patients with AD. In this study, trace elements and antioxidant enzymes associated with these elements were also evaluated in AD. Metals act as cofactors in the realization of many reactions in our body and participate in the structure of many enzymes (31). We evaluated superoxide dismutase, catalase, and glutathione peroxidase, which are antioxidant systems that prevent damage caused by reactive oxygen species in the bod. These levels were found to be low in AD. Changes in the levels of metals associated with these enzymes confirm metal cation dyshomeostasis in AD (31).

Transthyretin, a carrier protein in the blood, mediates the transport of various substances. One of these substances is Aβ and transthyretin mediates the removal of amyloid derivatives from the central nervous system (32). In addition, transthyretin undergoes a conformational change when exposed to metal cations such as copper, iron, zinc, and manganese. These metal ions change the binding affinity of transthyretin to Aβ. Transthyretin is converted to a protease that scavenges Aβ, thereby increasing Aβ elimination. It is one of the hypotheses that metal cations exert their effect on AD through transthyretin (30).

Copper homeostasis is regulated by two different activities. The first is enzymes that use copper as a cofactor, and the second is the proteins that transport copper. When copper is not used for vital catalytic functions, it participates in redox reactions. It generates hydroxyl radicals through the activation of the Haber-Weiss cycle and Fenton reactions (33). Copper unbound to ceruloplasmin is associated with redox-mediated toxicity. Ceruloplasmin-bound copper contains 5-10% of plasma copper and is in dynamic equilibrium with albumin, peptides, and amino acids (34). Metal accumulates in the mitochondria of copper-overloaded cells, and mitochondrial copper alterations are involved in neurodegenerative processes and apoptotic signaling (35).

Therefore, when the copper balance is disturbed, this may contribute to the development of AD, or the development of AD may disrupt copper homeostasis and the process may be exacerbated. The details of this mechanism are not fully known and need to be clarified. Knowing the mechanism will enable the production of metal cation-related treatment options.

Zinc in Alzheimer’s Disease

Zinc is the second most abundant trace element after iron in the human central nervous system. Because of the multifunctional properties of zinc, zinc dyshomeostasis can affect different biological activities. Zinc-based therapies are considered for AD because of the changes observed in zinc levels in human and animal studies (36).

Zinc is essential for brain function and participates in catalytic reactions for the continuation of life (19). High zinc influx at synapses contributes to synaptic plasticity, and zinc modulates long-term potentiation in the hippocampal CA3 region. The synaptic zinc cycle deteriorates with age. Therefore, zinc dysregulation contributes to cognitive impairment in AD (37,38).

Zinc levels affect APP processing, function, and degradation. NF-κB and p53, zinc-containing transcription factors, regulate APP synthesis. In addition, zinc correlates with the expression of secretases that are effective in APP proteolysis (39). Park et al. (40) showed that zinc reduced presenilin1 synthesis in mouse primary cortical culture and APP/PS1 mice. In this study, zinc induced cell death in a dose-dependent manner, and the increase in presenilin 1 synthesis was thought to be specifically related to zinc-induced cell death (40). Zinc binding can regulate the polymerization properties of Aβ. Because zinc is mainly released from synaptic vesicles in the central nervous system, it plays a key role in controlling the formation of synaptic Aβ oligomers and targeting Aβ oligomers to synaptic terminals (41). The ZnAβ oligomer is a cytotoxic Aβ oligomer, more toxic than the zinc-free form and has toxic effects on synaptic plasticity and long-term potentiation (42).

Zinc accumulation, as well as other metal cations, has been demonstrated in amyloid plaques in AD (29). It is also stated that Aβ exposed to the +2 form of zinc undergoes conformational changes (43). In metal cation dyshomeostasis in AD, the levels of some metals increase while those of others decrease. In a study conducted with 44 patients with AD and 41 healthy controls, it was determined that plasma zinc levels were significantly reduced in patients with AD. The researchers in this study interpreted this finding as a decrease in zinc in plasma due to its accumulation in the central nervous system (44).

It is emphasized that while zinc at low concentrations reduces amyloid aggregation, +2 loaded zinc at high concentrations can increase toxicity (45). As with other metal cations, the most important issue with zinc is balance. Disruption of this balance appears to be associated with diseases. Metal cation dyshomeostasis is accepted as one of the development mechanisms of AD and is among the future therapeutic targets.

Magnesium in Alzheimer’s Disease

Magnesium is a very important metal ion that participates in more than 300 enzymatic reactions in the human body. It is necessary for the regulation of muscle contraction, blood pressure, and insulin metabolism. In addition, magnesium must be present for the synthesis of DNA, RNA, and proteins (46).

Magnesium is also important for the nervous system. This is mainly due to the interaction of magnesium with the NMDA receptor, which contains a calcium channel with magnesium blockade. Low magnesium levels could theoretically be thought to amplify glutamatergic signaling. This may result in glutamate excitotoxicity, which leads to oxidative stress and neuronal death. Abnormal glutamatergic transmission is a predisposing factor in many neurological diseases, the most important of which is AD (47,48). Therefore, magnesium supplements are believed to be beneficial for many neurological diseases, especially AD. It is stated that inadequate and/or irregular nutrition may lead to magnesium deficiency, which is a risk factor for AD (48-50).

Studies have shown that plasma, cerebrospinal fluid, and erythrocyte magnesium concentrations are low in Alzheimer’s patients (51-54). In another study conducted with 15 Alzheimer’s patients, 15 mild cognitive impairment patients, and 15 healthy controls, magnesium levels were low in Alzheimer’s patients and patients with mild cognitive impairment. These findings were explained by the fact that magnesium deficiency may cause glutamate excitotoxicity (49). However, in several studies, no significant difference was found in magnesium levels between Alzheimer’s patients and healthy controls (55,56). Therefore, the relationship between AD and magnesium should be clarified by experimental and clinical studies. Barbagallo et al. (57) reported that the ionized form of magnesium is related to cognitive function rather than physical function, and the ionized form of magnesium should be considered when evaluating neurological diseases such as AD.

In addition, improvement in cognitive impairment was observed following magnesium administration in a mouse model of AD. The results of this study have been interpreted as suggesting that elevation of brain magnesium exerts synaptoprotective effects in AD, and magnesium supplementation may have therapeutic potential for the treatment of AD (58). In a study conducted in rats, it was emphasized that magnesium deficiency may lead to an increase in free radical oxygen species. The reducing effect on oxidative stress products may be considered as one of the mechanisms of the positive effects of magnesium supplementation in AD. In addition, intraperitoneal administration of magnesium sulfate showed a protective effect on cognitive functions in a streptozotocin-induced sporadic AD rat model (59).

Magnesium supplements are being considered as therapeutic targets for AD. It is necessary to clarify both the prophylactic and therapeutic efficacy of magnesium in AD.

CONCLUSION

The mechanism of AD and its relationship with metal cations are not fully understood, but metal dyshomeostasis is effective in AD. The inability of treatments based on the amyloid cascade hypothesis, which is the most accepted hypothesis in the development of AD, to show sufficient efficacy in AD indicates the existence of different mechanisms. Iron, copper, zinc, and magnesium dyshomeostasis is common in AD. Therefore, metal cation dyshomeostasis appears to be associated with AD. Through the mechanisms investigated in this review and future studies, iron, copper, zinc, and magnesium-based treatments may be particularly beneficial for AD.

Ethics

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: E.T., A.K., M.A., Concept: E.T., A.K., M.A., Design: E.T., A.K., M.A., Data Collection or Processing: E.T., A.K., M.A., Analysis or Interpretation: E.T., A.K., M.A., Literature Search: E.T., A.K., M.A., Writing: E.T., A.K., M.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

Aranda MP, Kremer IN, Hinton L, Zissimopoulos J, Whitmer RA, Hummel CH, et al. Impact of dementia: Health disparities, population trends, care interventions, and economic costs. J Am Geriatr Soc 2021; 69: 1774-83

Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019; 322: 1589-99

Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 2019; 179: 312-39

Walsh S, Merrick R, Milne R, Brayne C. Aducanumab for Alzheimer’s disease? BMJ 2021; 374: n1682

Shi M, Chu F, Zhu F, Zhu J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci 2022; 14: 870517

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9-21

Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol 2021; 20: 222-34

Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement 2021; 17: 1145-56

Ciccone L, Fruchart-Gaillard C, Mourier G, Savko M, Nencetti S, Orlandini E, et al. Copper mediated amyloid-β binding to Transthyretin. Sci Rep 2018; 8: 13744

Giacconi R, Giuli C, Casoli T, Balietti M, Costarelli L, Provinciali M, et al. Acetylcholinesterase inhibitors in Alzheimer’s disease influence Zinc and Copper homeostasis. J Trace Elem Med Biol 2019; 55: 58-63

Toffa DH, Magnerou MA, Kassab A, Hassane Djibo F, Sow AD. Can magnesium reduce central neurodegeneration in Alzheimer’s disease? Basic evidences and research needs. Neurochem Int 2019; 126: 195-202

Squitti R, Ghidoni R, Simonelli I, Ivanova ID, Colabufo NA, Zuin M, et al. Copper dyshomeostasis in Wilson disease and Alzheimer’s disease as shown by serum and urine copper indicators. J Trace Elem Med Biol 2018; 45: 181-8

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry 2021; 26: 5481-503

Das N, Raymick J, Sarkar S. Role of metals in Alzheimer’s disease. Metab Brain Dis 2021; 36: 1627-39

Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 2009; 1248: 14-21

Peng Y, Chang X, Lang M. Iron Homeostasis Disorder and Alzheimer’s Disease. Int J Mol Sci. 2021; 22: 12442

Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006; 17: 5-17

Masaldan S, Belaidi AA, Ayton S, Bush AI. Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease. Pharmaceuticals (Basel) 2019; 12: 93

Lei P, Ayton S, Bush AI. The essential elements of Alzheimer’s disease. J Biol Chem 2021; 296: 100105

Rogers JT, Venkataramani V, Washburn C, Liu Y, Tummala V, Jiang H, et al. A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity. J Neurochem 2016; 138: 479-94

Bandyopadhyay S, Rogers JT. Alzheimer’s disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochem Pharmacol 2014; 88: 486-94

Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012; 51: 5705-24

van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020; 16: 77-98

Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry 2020; 25: 2932-41

Tao Y, Wang Y, Rogers JT, Wang F. Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimers Dis 2014; 42: 679-90

Ghadery C, Pirpamer L, Hofer E, Langkammer C, Petrovic K, Loitfelder M, et al. R2* mapping for brain iron: associations with cognition in normal aging. Neurobiol Aging 2015; 3: 925-32

Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther 2021; 6: 49

Reichert CO, de Freitas FA, Sampaio-Silva J, Rokita-Rosa L, Barros PL, Levy D, et al. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases. Int J Mol Sci 2020; 21: 8765

Pithadia AS, Lim MH. Metal-associated amyloid-β species in Alzheimer’s disease. Curr Opin Chem Biol 2012; 16: 67-73

Ciccone L, Fruchart-Gaillard C, Mourier G, Savko M, Nencetti S, Orlandini E, et al. Copper mediated amyloid-β binding to Transthyretin. Sci Rep 2018; 8: 13744

Vural H, Demirin H, Kara Y, Eren I, Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer’s disease. J Trace Elem Med Biol 2010; 24: 169-73

Tien YT, Lee WJ, Liao YC, Wang WF, Jhang KM, Wang SJ, et al. Plasma Transthyretin as a Predictor of Amnestic Mild Cognitive Impairment Conversion to Dementia. Sci Rep 2019; 9: 18691

Sensi SL, Granzotto A, Siotto M, Squitti R. Copper and Zinc Dysregulation in Alzheimer’s Disease. Trends Pharmacol Sci 2018; 39: 1049-63

Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics 2016; 8: 887-905

Swerdlow RH. The neurodegenerative mitochondriopathies. J Alzheimers Dis 2009; 17: 737-51

Xie Z, Wu H, Zhao J. Multifunctional roles of zinc in Alzheimer’s disease. Neurotoxicology. 2020; 80: 112-23

Pan E, Zhang XA, Huang Z, Krezel A, Zhao M, Tinberg CE, et al. Vesicular zinc promotes presynaptic and inhibits postsynaptic long-term potentiation of mossy fiber-CA3 synapse. Neuron 2011; 71: 1116-26

Datki Z, Galik-Olah Z, Janosi-Mozes E, Szegedi V, Kalman J, Hunya ÁG, et al. Alzheimer risk factors age and female sex induce cortical Aβ aggregation by raising extracellular zinc. Mol Psychiatry 2020; 25: 2728-41

Wang CY, Wang T, Zheng W, Zhao BL, Danscher G, Chen YH, et al. Zinc overload enhances APP cleavage and Aβ deposition in the Alzheimer mouse brain. PLoS One 2010; 5: e15349

Park IH, Jung MW, Mori H, Mook-Jung I. Zinc enhances synthesis of presenilin 1 in mouse primary cortical culture. Biochem Biophys Res Commun 2001; 285: 680-8

Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 2009; 29: 4004-15

Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-53

Lee MC, Yu WC, Shih YH, Chen CY, Guo ZH, Huang SJ, et al. Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer’s disease. Sci Rep 2018; 8: 4772

Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, et al. Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals 2010; 23: 173-9

August A, Schmidt N, Klingler J, Baumkötter F, Lechner M, Klement J, et al. Copper and zinc ions govern the trans-directed dimerization of APP family members in multiple ways. J Neurochem 2019; 151: 626-41

Gröber U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients 2015; 7: 8199-226

Clerc P, Young CA, Bordt EA, Grigore AM, Fiskum G, Polster BM. Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation. PLoS One 2013; 8: e79982

Olloquequi J, Cornejo-Córdova E, Verdaguer E, Soriano FX, Binvignat O, Auladell C, et al. Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications. J Psychopharmacol 2018; 32: 265-75

Balmuș IM, Strungaru SA, Ciobica A, Nicoara MN, Dobrin R, Plavan G, et al. Preliminary Data on the Interaction between Some Biometals and Oxidative Stress Status in Mild Cognitive Impairment and Alzheimer’s Disease Patients. Oxid Med Cell Longev 2017; 2017: 7156928

Kirkland AE, Sarlo GL, Holton KF. The Role of Magnesium in Neurological Disorders. Nutrients 2018; 10: 730

Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect 1991; 3: 231-58.

Boström F, Hansson O, Gerhardsson L, Lundh T, Minthon L, Stomrud E, et al. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiol Aging 2009; 30: 1265-71

Borella P, Giardino A, Neri M, Andermarker E. Magnesium and potassium status in elderly subjects with and without dementia of the Alzheimer type. Magnes Res 1990; 3: 283-9.

Brackenridge CJ, McDonald C. The concentrations of magnesium and potassium in erythrocytes and plasma of geriatric patients with psychiatric disorders. Med J Aust 1969; 2: 390-4

Cilliler AE, Ozturk S, Ozbakir S. Serum magnesium level and clinical deterioration in Alzheimer’s disease. Gerontology 2007;53: 419-22

Koç ER, Ilhan A, Zübeyde Aytürk, Acar B, Gürler M, Altuntaş A, et al. A comparison of hair and serum trace elements in patients with Alzheimer disease and healthy participants. Turk J Med Sci 2015; 45: 1034-9

Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ. Altered ionized magnesium levels in mild-to-moderate Alzheimer’s disease. Magnes Res 2011; 24: S115-21

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol Brain 2014; 7: 65

Xu ZP, Li L, Bao J, Wang ZH, Zeng J, Liu EJ, et al. Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer’s model. PLoS One 2014; 9: e108645.